Trial Profile
A Multicentre Double-Blinded Randomized Head-to-Head Study.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 02 Aug 2017
Price :
$35
*
At a glance
- Drugs Olanzapine (Primary) ; Sertindole (Primary)
- Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Acronyms SEROLA
- 01 Nov 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 19 Dec 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 19 Dec 2011 Planned end date changed from 1 Feb 2011 to 1 Jun 2012 as reported by ClinicalTrials.gov.